Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 7/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10729595 | 0.87 | TYR (0.38) | TYRALOX15HTTALDH1A1NR1I2 | |
| SCHEMBL10729070 | 0.84 | TYR (0.36) | TYRALOX15HTTALDH1A1NR1I2 | |
| SCHEMBL10732542 | 0.84 | TYR (0.36) | TYRALOX15HTTALDH1A1NR1I2 | |
| SCHEMBL10727308 | 0.84 | TYR (0.36) | TYRALOX15HTTALDH1A1NR1I2 | |
| SCHEMBL10729151 | 0.84 | TYR (0.36) | TYRALOX15HTTALDH1A1NR1I2 | |
| SCHEMBL11115405 | 0.83 | TYR (0.49) | TYRALOX15HTTALDH1A1NR1I2 | |
| SCHEMBL2946516 | 0.81 | TYR (0.49) | TYRALOX15HTTMEN1KMT2A | |
| SCHEMBL13917511 | 0.81 | TYR (0.42) | TYRALOX15HTTALDH1A1NR1I2 | |
| SCHEMBL10732587 | 0.81 | TYR (0.37) | TYRALOX15HTTALDH1A1NR1I2 | |
| SCHEMBL11111809 | 0.80 | ACE2 (0.41) | TYRALOX15HTTALDH1A1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173867-B2 | Treatment of immune dysregulation using cannabinoid derivatives | IMMUGEN PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | IMMUGEN PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-8586767-B2 | Method for treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG RICK (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | TRAVIS CRAIG RICK (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | TRAVIS CRAIG RICK (US) | 2012-05-17 | — | — | US | disclosed |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG R | 2008-05-08 | — | — | US | disclosed |
| US-20070179135-A1 | Cannabinoid derivatives | TRAVIS CRAIG R | 2007-08-02 | — | — | US | disclosed |
| US-7105685-B2 | Viricides treating Human Immunodeficiency Viruses; antitumor agents | TRAVIS CRAIG R | 2006-09-12 | — | — | US | disclosed |
| US-20040138315-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004016254-A2 | CONTRACEPTIVE METHODS AND FORMULATIONS | IMMUGEN PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003080043-A1 | TOPICAL FORMULATIONS OF RESORCINOLS AND CANNIBINOIDS AND METHODS OF USE | IMMUGEN PHARMACEUTICALS, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030158191-A1 | Cannabinol derivatives | TRAVIS CRAIG R (US) | 2003-08-21 | — | — | US | disclosed |
| US-6566560-B2 | Using to attenuate the growth of a neoplasm | IMMUGEN PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| WO-2002026224-A9 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS INC (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002026224-A2 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-20020037923-A1 | Resorcinolic compounds | IMMUGEN PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189603-A2 | TREATMENT OF IMMUNE DISEASES LIKE HIV DISEASE AND NEOPLASTIC DISORDERS | Immugen Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6274635-B1 | ANTITUMOR AGENTS | IMMUGEN PHARMACEUTICALS INC. | 2001-08-14 | — | — | US | disclosed |
| WO-2000056303-A2 | TREATMENT OF IMMUNE DISEASES | IMMUGEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | CNR2, CNR1, GPR18 | TYR 3677/4885ALOX15 480/4885HTT 3857/4885 |
| US-20030158191-A1 | Cannabinol derivatives | CNR2, CNR1, GPR18 | TYR 4218/4885ALOX15 906/4885HTT 1725/4885 |
| US-20020037923-A1 | Resorcinolic compounds | VHL, HRAS, CYP46A1 | TYR 3151/4885ALOX15 2533/4885HTT 3522/4885 |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | CNR2, CNR1, GPR18 | TYR 3677/4885ALOX15 480/4885HTT 3857/4885 |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | CNR2, CNR1, ICOS | TYR 3703/4885ALOX15 357/4885HTT 3011/4885 |
| US-20070179135-A1 | Cannabinoid derivatives | CNR2, CNR1, GPR18 | TYR 3604/4885ALOX15 1156/4885HTT 2784/4885 |
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | PTGS1, PTGIS, PTGES | TYR 2335/4885ALOX15 20/4885HTT 1732/4885 |
| US-20040138315-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | PTGS1, PTGIS, PTGES | TYR 2335/4885ALOX15 20/4885HTT 1732/4885 |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | CNR1, CNR2, ICOS | TYR 4208/4885ALOX15 340/4885HTT 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.